Cyrille Coustal

Cyrille Coustal

Auto-generated profile, based on publicly available information

Cyrille Coustal

Department of Internal Medicine, Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JHJerome Hadjadj
Jerome Hadjadj
YNYann Nguyen
Yann Nguyen
DMDalila Mouloudj
Dalila Mouloudj
RBRim Bourguiba
Rim Bourguiba
MHMael Heiblig
Mael Heiblig
JDJeremie Dion
Jeremie Dion
Objectives Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies. Methods Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy. Complete response (CR) was defined by a clinical remission, C-reactive protein (CRP) ≤10 mg/L and a ≤10 mg/day of prednisone-equivalent therapy, and partial response (PR) was defined by a clinical remission and a 50% reduction in CRP levels and glucocorticoid dose. Results 110 patients (median age 71 (68–79) years) who received 194 targeted therapies were included: 78 (40%) received Janus kinase (JAK) inhibitors (JAKi), 51 (26%) interleukin (IL)-6 inhibitors, 33 (17%) IL-1 inhibitors, 20 (10%) tumour necrosis factor (TNFα) blockers and 12 (6%) other targeted therapies. At 3 months, the overall response (CR and PR) rate was 24% with JAKi, 32% with IL-6 inhibitors, 9% with anti-IL-1 and 0% with TNFα blockers or other targeted therapies. At 6 months, the overall response rate was 30% with JAKi and 26% with IL-6 inhibitors. Survival without treatment discontinuation was significantly longer with JAKi than with the other targeted therapies. Among patients who discontinued treatment, causes were primary failure, secondary failure, serious adverse event or death in 43%, 14%, 19% and 19%, respectively, with JAKi and 46%, 11%, 31% and 9%, respectively, with IL-6 inhibitors. Conclusions This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials.

10 October 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
CCCyrille Coustal
Cyrille Coustal
RGRadjiv Goulabchand
Radjiv Goulabchand
PLPierre Labauge
Pierre Labauge
PGPhilippe Guilpain
Philippe Guilpain
CCClarisse Carra-Dallière
Clarisse Carra-Dallière
XAXavier Ayrignac
Xavier Ayrignac
Background and Objectives: CTLA4 deficiency (CTLA4d) is a disease with multisystem auto-immune features, including neurological manifestations. We aimed to describe neurological involvement in these patients. Methods: We performed a cross-sectional observational study using the French Reference Centre for Primary Immunodeficiencies (CEREDIH) registry, plus a surveillance in national society networks. Participants with confirmed CTLA4d and neurological involvement were included. Clinical, laboratory and radiological features were collected, as well as treatments. Available MRI were double-reviewed. Results: Among 70 patients with CTLA4d, 13 patients (21%) had neurological involvement. Neurological symptoms began at a median age of 18 [15-45] years, mostly occurring after systemic manifestations (median delay: 8.5 [4.5-10.5] years). Main symptoms included headaches, focal deficit (54% each) and seizures (38%). MRI detected at least one large contrast-enhancing lesion in eight patients. Lesions reminiscent of multiple sclerosis lesions were found in six patients. Cerebellar (6 patients) and large spinal cord lesions (3 patients) were common. Ten patients were treated with Abatacept, of whom nine (90%) showed good clinical and radiological response. Discussion: Neurologic involvement is common among patients with CTLA4d. Despite its rarity, and considering the suspected efficacy of Abatacept, neurologists should be aware of the characteristics of CTLA4d neurological involvement.

10 February 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Pascale PalassinPascale Palassin
Pascale Palassin
JFJean-Luc Faillie
Jean-Luc Faillie
CCCyrille Coustal
Cyrille Coustal
XQXavier Quantin
Xavier Quantin
DTDelphine Topart
Delphine Topart
AMAlexandre T.J. Maria
Alexandre T.J. Maria

28 July 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
CCCyrille Coustal
Cyrille Coustal
ATAurélie Du Thanh
Aurélie Du Thanh
FRFrançois Roubille
François Roubille
EAEric Assenat
Eric Assenat
AMAlexandre T.J. Maria
Alexandre T.J. Maria

4 October 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
AMAlexandre T.J. Maria
Alexandre T.J. Maria
CDClement Delmas
Clement Delmas
CCCyrille Coustal
Cyrille Coustal
Pascale PalassinPascale Palassin
Pascale Palassin
FRFrançois Roubille
François Roubille